

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 5, 2010
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 5, 2010.

2. Welcome

Debbie Tapley, RPh, called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Debbie Tapley introduced the Committee's new member, Dr. Bruce Johnson.

3. Committee Members Present:

Jony Bolinger, MD
Greg Browning, MD
Jim Lindsay, MD

Sara Lindsey, MD
Kelly Jones, PharmD
Tan Platt, MD

Debbie Tapley, RPh
Edward Vess, RPh

DHHS Staff Present:

Emma Forkner, Director
Felicity Myers, PhD
James Assey, RPh
Felicity Myers, PhD
Deidra Singleton, JD
Valeria Williams

Other Representation:

First Health Services – Bryan Amick, PharmD
First Health Services – Mary Roberts, RPh
Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 5, 2009.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. SC DHHS Presentation

Director Forkner presented information regarding bleak outlook of the current budgetary condition of SC DHHS, which is similar to many other states. An estimated 5,000 children are added to Medicaid rolls every month, and Medicaid currently provides care to 43% of the children in SC. Implications of the HITECH Act were discussed. The impact of the various healthcare reform measures currently being debated at the federal level was discussed, with emphasis on meaningful use requirements. Specific items of discussion were the potential expansion of Medicaid and its effect on South Carolina and the role of e-prescribing as a component of the expansion of health information technology.

C. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

COMPANY	SPEAKER	DRUG
Pfizer, Inc.	Donna King, PhD	Genotropin®
Novo Nordisk	Cheryl Pryor, PharmD	Norodotropin®
Genentech	Elaine Moreland, MD	Nutropin®
Teva	Jennifer Pritchett	Tev-Tropin®
Merck & Co.	Vicki Star, MD, FACR	Nasonex®
AstraZeneca	Michelle McKee, PharmD	Nexium®
Takeda	Keith Szymanski, PharmD	Dexilant® Actos®
GlaxoSmithKline	Steve Simmons, PharmD, FASHP	Avandia®

D. Drug Classes for Review

Mary Roberts, RPh, First Health Services Corporation, led the discussion for the following drug classes:

Growth Hormone	Thiazolidinediones
Nasal Steroids	Thiazolidinedione/Sulfonylurea Combinations
Proton Pump Inhibitors	Thiazolidinedione/Biguanide Combinations

The following are the recommendations of the P & T Committee:

GROWTH HORMONE	
Preferred	Non-Preferred
GENOTROPIN	HUMATROPE
NORDITROPIN	OMNITROPE
NUTROPIN	SAIZEN
	TEV-TROPIN
	ZORBTIVE
NASAL STEROIDS	
Preferred	Non-Preferred
<p>The Committee approved the change to make fluticasone as the sole preferred agent with the following conditions:</p> <ul style="list-style-type: none"> -At least one of the agents indicated for age two and above (Nasonex or Veramyst) should be available for children age 12 and under without the step therapy requirement. -After failure on fluticasone, at least one of the other agents should be available automatically at point-of-sale. 	
PROTON PUMP INHIBITORS	
Preferred	Non-Preferred
NEXIUM	ACIPHEX
OMEPRAZOLE OTC	KAPIDEX / DEXILANT
PREVACID SOLUTABS*	LANSOPRAZOLE
PRILOSEC OTC	NEXIUM SUSPENSION
	OMEPRAZOLE RX
	PANTOPRAZOLE
	PREVACID
	PRILOSEC RX
	PROTONIX
*Prevacid Solutabs preferred for beneficiaries age 12 and under.	
THIAZOLIDINEDIONES	
Preferred	Non-Preferred
AVANDIA	ACTOS 30 & 45 MG
ACTOS 15MG	
Approved with the recommendation that a robust outreach effort aimed at physicians, pharmacists, and beneficiaries be undertaken to prepare for this change.	
THIAZOLIDINEDIONE-SULFONYLUREA COMBINATIONS	
Preferred	Non-Preferred
AVANDARYL	DUETACT
THIAZOLIDINEDIONE-METFORMIN COMBINATIONS	
Preferred	Non-Preferred
AVANDAMET	ACTOPLUS MET

5. Old Business

Information presented regarding differences in refill rate among the various albuterol inhaler products.

6. New Business

None

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS:

Growth Hormone	Thiazolidinediones
Nasal Steroids	Thiazolidinedione/Sulfonylurea Combinations
Proton Pump Inhibitors	Thiazolidinedione/Biguanide Combinations

8. Closing Comments

The next meeting will be held on Wednesday, August 4, 2010, at 4:00 PM at the same location.

9. Adjournment

The meeting adjourned at 5:55 PM.